Kinase Inhibitors – Benefit Your Influence Now by Discovering Their Sales Potentials Do you want to find sales potentials of protein kinase inhibitors for treating cancer? You can now explore the latest research and development and market predictions. Our new study shows you R&D trends, results, opportunities and multilevel revenue forecasts.
Visiongain’s report shows you what is possible for drugs using protein kinase inhibition. That way you assess the future of cancer treatment. Find progress in that rising industry and market, discovering expected progress and sales, including the influence of new products.
Avoid missing out. With our research and analysis you assess trends, companies and products, benefiting your reputation for technological and commercial insight. That way discover what is possible from 2015.
Progress of that industry – discover prospects for those novel anti-cancer medicines Are you tired of struggles to find business data on cancer therapy? Instead benefit your work through our new study, seeing how to help your data searches, analyses, decisions, proposals and presentations.
With our new study you explore the future of those therapies. Read on, then, to investigate that industry and see how high its future sales could go.
Forecasts and other information showing technical, clinical and commercial possibilities The new study gives you sales predictions to 2025 at overall world market, submarket, company, product and national level. See what the future holds for those advances in cancer therapy. For kinase-inhibiting drugs you investigate where demand and money lie.
In our work you receive 83 tables, 73 charts and two interviews with other authorities. Besides giving revenue predictions, our new analysis shows recent results, growth rates and market shares.
Although no single study covers everything, the following sections show how our new investigation benefits your work.
Forecasting of that world market and its segments – what’s possible for those treatments? What is the potential of that biomedical industry? What are the secrets of its progress? Discover in our report overall world revenue to 2025 for inhibition of protein kinases.
There you also find individual revenue predictions to 2025 for eight submarkets at world level: • Bcr-Abl tyrosine-kinase inhibitors (TKI) • Angiogenesis inhibitors • EGFR inhibitors • mTOR inhibitors • BRAF and MEK inhibitors • Other kinase inhibitors • Pipeline drugs • Generics and other agents.
Our work investigates products, uses and revenues past and future. That way you assess outlooks for expansion in trade, seeing where potential sales increases can appear, helping you stay ahead.
The new study also explores competition. There you investigate activities of developers, producers and marketers of kinase inhibiting medicines, understanding their challenges, trends and outlooks. You also examine revenues by product.
Product forecasts – investigate sales potentials of existing and expected therapies How will top marketed and expected kinase treatments perform to 2025 at world level?
Our new analysis shows you individual revenue predictions for 28 marketed products, including these drugs: • Glivec (imatinib) • Sprycel (dasatinib) • Tasigna (nilotinib) • Tarceva (erlotinib) • Nexavar (sorafenib) • Sutent (sunitinib) • Afinitor (everolimus) • Imbruvica (ibrutinib).
That study includes profiles for 23 medicines in development and revenue forecasts for seven leading drug candidates, including these agents: • Venetoclax (ABT-199) • Duvelisib (IPI-145) • Buparlisib (BKM120) • Cobimetinib (GDC-0973).
With our analysis you discover sales potentials for leading brands of those enzyme inhibitors. Discover what is possible, from 2015, for transforming that industry and market.
Also our survey splits its overall world market into geographical revenue predictions.
National markets for those drug sales – what does the future hold? Advances in biotechnology and healthcare expand use of anti-cancer drugs, including protein kinase inhibitors. Our study shows you prospects for those sales in developed and developing regions.
There see individual revenue forecasting to 2025 for 11 countries: • United States (US) • Japan • Germany, France, United Kingdom (UK), Italy and Spain, also with overall EU prediction • Brazil, Russia, India and China (BRIC nations).
With our analysis you investigate countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.
Also how do events, challenges and advances in technology affect that industry and market? Our report shows you, discussing progress, policies and trends.
Forces affecting developers, producers and sellers of those pharmaceuticals Our study explains issues, events and R&D affecting that oncology from 2015, including these advances: • Cyclin-dependent kinase 4/6 and ALK inhibitors in development • Bruton’s tyrosine kinase and PI3K agents for the future • MEK and BRAF inhibition – prospects for new treatments.
Also explore these trends and influences, among others, assessing their impact: • Stratification of patients and cancer genomics for more-personalised medicine • Ageing populations and rising cancer prevalence increasing demand • Generic competition – challenges for original branded drugs • Biologics – including monoclonal antibodies (mAbs) • Combination therapies – potential for improvements in treating patients.
Our study explains that industry’s strengths, weaknesses, opportunities and threats. It also explores social, technological, economic and political questions. Those methods let you analyse that market, its progress and potential, discovering from 2015 what is possible.
Kinase inhibitors for treating cancer – what revenues are likely by 2019? What happens next? From 2015, protein kinase inhibitors for treating cancer patients hold great potential for investments, technological advances and sales. Visiongain predicts the world market for those products will grow to $31.2bn in 2019, with further expansion to 2025.
In particular our study explores activities and potentials of nine companies, forecasting revenues to 2025 for seven firms: • Novartis • Pfizer • Roche • Bristol-Myers Squibb • Bayer • AstraZeneca • Gilead Sciences.
Our survey also shows interviews by Visiongain with other authorities on anti-cancer kinase inhibitors: • Infinity Pharmaceuticals • LYMMCARE (Lymphoma and Myeloma Center Amsterdam).
From 2015, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potentials.
Ways Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025 helps In these seven main ways, our new investigation benefits your work: • Kinase inhibitors revenue to 2025 – discover the sales potential of that cancer treatments market • 8 main submarkets’ revenues to 2025 – explore that industry’s segments at world level, finding the most lucrative and fast growing product groups • 35 drugs’ and 7 leading companies’ revenues to 2025 – find sales predictions for top medicines and their producers, seeing how they can compete and succeed • 11 national markets’ forecasts to 2025 – investigate leading countries in the Americas, Europe and Asia for revenues from those drugs • Activities of established, rising and emerging companies – assess organisations’ products, capabilities, advances and outlooks, also getting opinions from interviews • R&D reviews and forecasts – explore technological, clinical and commercial opportunities and outlooks, helping you succeed • Analysis of what stimulates and restrains that pharmaceuticals market – assess challenges and strengths, helping you compete and gain advantages.
That study, by Visiongain’s in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.
Information there found nowhere else, benefiting your research, analyses and plans Our report gives independent analysis. With it you receive business intelligence found only in our work, seeing where commercial prospects are most rewarding.
With that investigation you are less likely to fall behind in information or miss opportunity. Discover now how you can help your research, analysis, decisions, presentations and proposals, reducing wasted time and benefiting your authority.
Our new analysis is for everyone assessing the present and future of cancer treatment. That way you explore results, trends, opportunities and sales predictions. So stay ahead in knowledge – please request our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the Protein Kinase Inhibitor Market for Cancer Treatments, 2015 1.2 Benefits of This Report 1.2.1 How This Report Delivers 1.2.2 Main Questions Answered by this Analytical Study 1.3 Who is This Report For? 1.4 Methods of the Study 1.5 Frequently Asked Questions (FAQ) 1.6 Associated Visiongain Reports 1.7 About Visiongain
2. Introduction to Anti-Cancer Kinase Inhibitors 2.1 What are Protein Kinases and Protein Kinase Inhibitors? 2.2 Protein Kinases in Oncology 2.3 Glossary
3. Leading Anti-Cancer Kinase Inhibitor Drugs: Forecasts and Discussions, 2015-2025 3.1 Brc-Abl Inhibitors – Transforming Chronic Myeloid Leukaemia from a Fatal Diagnosis To a Managed Lifestyle 3.1.1 Glivec/Gleevec (imatinib) – Novartis 3.1.2 Sprycel (dasatinib) – Bristol-Myers Squibb 3.1.3 Tasigna (nilotinib) – Novartis 3.1.4 Bosulif (bosutinib) – Pfizer 3.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals 3.2 EGFR Inhibitors Target a Mutation-Positive Market 3.2.1 Tarceva (erlotinib) – Roche/Astellas 3.2.2 Iressa (gefinitib) – AstraZeneca 3.2.3 Gilotrif/Giotrif (afatinib) – Boehringer Ingelheim 3.3 Angiogenesis Inhibitors Have a Variety of Indications 3.3.1 Nexavar (sorafenib) – Bayer/Onyx 3.3.2 Sutent (sunitinib) – Pfizer 3.3.3 Votrient (pazopanib) – Novartis 3.3.4 Inlyta (axitinib) – Pfizer 3.4 BRAF and MEK Inhibitors: A Promising Combination 3.4.1 Zelboraf (vemurafenib) – Roche 3.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – Novartis 3.5 mTOR Inhibitors Have a New Entrant 3.5.1 Afinitor/Votubia (everolimus) – Novartis 3.5.2 Torisel (temsirolimus) – Pfizer 3.5.3 Zydelig (idelalisib) – Gilead Sciences 3.6 Other Leading Cancer Inhibitors Are a Varied Group 3.6.1 Imbruvica (ibrutinib) – J&J/Pharmacyclics/AbbVie 3.6.2 Jakavi/Jakafi (ruxolitinib) – Novartis/Incyte 3.6.3 Xalkori (crizotinib) – Pfizer 3.6.4 Cometriq (cabozantinib) – Exelixis 3.6.5 Caprelsa (vandetanib) – AstraZeneca 3.6.6 Tyverb/Tykerb (lapatinib) – Novartis 3.6.7 Stivarga (regorafenib) – Bayer 3.6.8 Zykadia (ceritinib, LDK378) – Novartis 3.6.9 Ibrance (palbociclib) – Pfizer 3.6.10 Alectinib (AF802) – Roche
4. Anti-Cancer Kinase Inhibitors: World Market Outlook and Forecast, 2015-2025 4.1 Global Anti-Cancer Kinase Inhibitors Market: Leading Kinase Inhibitors in 2014 4.2 World Anti-Cancer Kinase Inhibitors Market: Revenue Forecasts and Change in Market Shares by Class 2015-2025 4.3 Bcr-Abl Inhibitors Lead the Anti-Cancer Kinase Inhibitors Market in 2015 4.3.1 Drivers and Restraints of the Bcr-Abl Kinase Inhibitors Market 2015-2025 4.4 Novel Kinase Inhibitors Will Dominate the Market As They Cover a Broad Range 4.4.1 Drivers and Restraints of these Other Kinase Inhibitors 2015-2025
5. Leading National Markets for Anti-Cancer Kinase Inhibitors, 2015-2025 5.1 Regional Breakdown of the Global Anti-Cancer Kinase Inhibitors Market, 2014 5.2 World Anti-Cancer Kinase Inhibitors Market: Regional Forecast 2015-2025 5.3 How Will Regional Market Shares Change through to 2025? 5.4 The US Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.4.1 Drivers and Restraints of the US Anti-Cancer Kinase Inhibitors Market 2015-2025 5.5 The EU Anti-Cancer Kinase Inhibitors Market 2015-2025 5.5.1 Drivers and Restraints of the EU Anti-Cancer Kinase Inhibitors Market 2015-2025 5.5.2 German Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.5.3 French Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.5.4 Italian Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.5.5 UK Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.5.6 Spanish Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.6 Japanese Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.7 The Anti-Cancer Kinase Inhibitors Emerging Market: BRIC 2015-2025 5.7.1 China: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.7.2 India: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.7.3 Brazil: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025 5.7.4 Russia: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2015 6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development 6.1.1 LEE-011 – Novartis 6.1.2 Abemaciclib (LY2835219) – Eli Lilly 6.2 ALK Inhibitors in Development 6.2.1 Brigatinib (AP26113) – ARIAD Pharmaceuticals 6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development 6.3.1 Venetoclax (ABT-199/RG7601/GDC-0199)– Roche/AbbVie 6.3.2 Duvelisib (IPI-145) – Infinity Pharmaceuticals/AbbVie 6.3.3 Buparlisib (BKM120) – Novartis 6.3.4 ONO-4059 – ONO Pharmaceutical/Gilead Sciences 6.3.5 Copanlisib (BAY 80-6946) – Bayer 6.3.6 Pictilisib (GDC-0941/RG7321) – Roche 6.3.7 BEZ235 – Novartis 6.4 MEK and BRAF Inhibitors in Development 6.4.1 Cobimetinib (GDC-0973/XL518) – Exelixis/Roche 6.4.2 Encorafenib (LGX818) & Binimetinib (MEK162)– Array BioPharma 6.4.3 Selumetinib (AZD 6244) – AstraZeneca/Array BioPharma 6.5 Other Anti-Cancer Kinase Inhibitors in Development 6.5.1 Volasertib – Boehringer Ingelheim 6.5.2 Neratinib (PB272) – Puma Biotechnology 6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo/ArQule 6.5.4 Dovitinib (TKI258) – Novartis 6.5.5 Dacomitinib – Pfizer 6.5.6 Rociletinib (CO-1686) – Clovis Oncology 6.5.7 Entrectinib (RXDX-101) – Ignyta 6.5.8 INC280 and EGF816 – Novartis
7. Leading Companies in the Anti-Cancer Kinase Inhibitors Market, 2015 7.1 Leading Companies in the Anti-Cancer Kinase Inhibitors Market by Revenue, 2014 7.1.1 Leading Anti-Cancer Kinase Inhibitors Manufacturers: Revenue Forecasts, 2015-2025 7.2 Leading Anti-Cancer Kinase Inhibitor Company Profiles 7.2.1 Novartis: Interesting Developments and a Continued Lead on the Market 7.2.2 Pfizer: Advancing Closer to Novartis’ Lead 7.2.3 Roche: A Global Giant in Cancer Treatment 7.2.4 Bristol-Myers Squibb’s Success is Tied to Sprycel 7.2.5 Bayer Healthcare: Nexavar and Stivarga 7.2.6 AstraZeneca Needs the US Market To Succeed 7.2.7 Gilead Sciences 7.3 Other Companies 7.3.1 AbbVie 7.3.2 Boehringer Ingelheim BioXcellence
8. Qualitative Analysis of the Anti-Cancer Kinase Inhibitors Market, 2015-2025 8.1 SWOT Analysis of the Anti-Cancer Kinase Inhibitors Market 8.2 Strengths 8.2.1 Personalised Medicine is a Strong Trend in Cancer Treatment 8.2.2 Targeted Kinase Inhibitors are Generally Well-Tolerated 8.2.3 Strong Pipeline of Novel Inhibitors Will Drive Market Growth 8.2.4 Oral Dosage is the Preferred Treatment 8.3 Weaknesses 8.3.1 High-Cost of Treatment May Restrain the Market 8.3.2 Ease of Manufacturing Small Molecule Drugs 8.3.3 Monoclonal Antibodies are More Specific than Small Molecules 8.4 Opportunities 8.4.1 Ageing Populations and Rising Cancer Prevalence Will Increase Demand for Treatment 8.4.2 Investment into Research May Lead to Improved Targeted Treatments 8.4.3 Combination Therapies Bring Additive Benefits 8.5 Threats 8.5.1 Regulations: Can they Restrain the Market? 8.5.2 Multiple Companies Competing 8.6 STEP Analysis of the Anti-Cancer Kinase Inhibitors Market
9. Research Interviews 9.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States 9.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications 9.1.2 Combining Therapies Offers Significant Benefit to Patients 9.1.3 Potential in Rheumatoid Arthritis and Blood Cancers 9.2 Interview with Dr Marcel Spaargaren, Associate Professor, LYMMCARE (Lymphoma and Myeloma Center Amsterdam) 9.2.1 Combining Two Kinase Inhibitor Therapeutics 9.2.2 Expectations for Kinase Inhibitor Therapies as Cancer Treatments 9.2.3 The Future of B-Cell Receptor Inhibitors
10. Conclusions from the Research and Analysis 10.1 World Anti-Cancer Kinase Inhibitors Market: Outlook from 2015 10.1.1 Recent Launches of Innovative Drugs and a Robust Pipeline Will Drive Market Growth 10.2 Opportunities in Developed and Developing National Pharma Markets Expanding Those Drug Sales
AbbVie Amgen Apotex ARIAD Pharmaceuticals ArQule Array BioPharma ASCO (American Society of Clinical Oncology) Astellas AstraZeneca Avilion Group Bayer Healthcare Boehringer Ingelheim BioXcellence Brazilian Unified Health System (SUS) Bristol-Myers Squibb CDC (Centers for Disease Control and Prevention) Chia Tai Tianging Pharma China Food and Drug Administration CHMP (Committee for Medicinal Products for Human Use) Chugai Pharmaceuticals Clovis Oncology Consumer Healthcare Venture Daiichi Sankyo Group DIPP (Department of Industrial Policy and Promotion) Eli Lilly EMA (European Medicines Agency) European Commission European Organisation for Research and Treatment and Cancer (EORTC) Exelixis FDA (US Food and Drug Administration) Genentech (subsidiary of Roche) Gilead Sciences GlaxoSmithKline GSK Consumer Healthcare Ignyta Incyte Infinity Pharmaceuticals Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) Janssen Pharmaceutical (subsidiary of J&J) Jiangsu Hansoh Pharma Johnson & Johnson Laborers Health and Welfare Trust Fund for Northern California Merck KGaA MHLW (Ministry of Health, Labour, and Welfare, Japan) Mylan NATCO National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) NCCN (National Comprehensive Cancer Network) NHS (National Health Service, UK) NICE (the National Institute for Health and Care Excellence, UK) Novartis ONO Pharmaceuticals Onyx (part of Amgen) ORP (Oncology Research Program) Orphan Biovitrum (Sobi) OSI Pharmaceuticals Otsuka Pharmaceutical Peregrine Pharmaceuticals Pfizer Pharmacyclics Pharmstandard Plexxikon (Daiichi Sankyo Group) Puma Biotechnology Qiagen Roche Sun Pharma Teva Pharmaceutical Industries UCSF (University of California, San Francisco) United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund Warner-Lambert/Parke-Davis Wyeth
Download sample pages
Complete the form below to download your free sample pages for Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
